Abstract Number: LB16 • ACR Convergence 2025
Mepolizumab Reduces End-Organ Manifestations Compared with Standard of Care in Patients with EGPA and HES: A US Real-world Analysis
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are rare systemic diseases characterized by persistent eosinophilia and tissue infiltration, resulting in end-organ dysfunction…Abstract Number: 0421 • ACR Convergence 2025
Inflammatory Orbital Diseases: Pediatric Case Series From a Tertiary Care Center
Background/Purpose: Orbital inflammatory diseases in the pediatric population present diagnostic and therapeutic challenges due to variable clinical manifestations, limited prospective data, and lack of standardized…Abstract Number: 0718 • ACR Convergence 2025
Incidence of Venous Thromboembolism in Patients with ANCA-Associated Vasculitides – a Nationwide Registry-Based Study from Sweden
Background/Purpose: Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV) are rare yet severe autoimmune diseases. Previous studies have indicated that patients with AAV have an increased risk…Abstract Number: 1602 • ACR Convergence 2025
Biomarkers of Innate Immune Activation to Identify Non-Response to Rituximab in Granulomatosis with Polyangiitis
Background/Purpose: Innate immune activation plays a key role in granulomatosis with polyangiitis (GPA), contributing to vascular inflammation via neutrophil extracellular traps, immune complexation (IC), and…Abstract Number: 1769 • ACR Convergence 2025
Classification of Relapses of Eosinophilic Granulomatosis with Polyangiitis After Two-Years of Treatment with Anti-Interleukin-5/Receptor Therapy
Background/Purpose: Results from the ongoing open-label extension (OLE) of the MANDARA trial (NCT04157348) have demonstrated the efficacy of two years of anti-interleukin-5/receptor (anti-IL-5/R) therapies in…Abstract Number: 2519 • ACR Convergence 2025
A Disproportionality Analysis of FDA Adverse Event Reporting System (FAERS) Events for Avacopan
Background/Purpose: Avacopan, a C5a receptor inhibitor, is used as an adjunctive treatment for ANCA-associated vasculitis. Previous studies have highlighted its efficacy in reducing glucocorticoid use…Abstract Number: 0724 • ACR Convergence 2025
Risk of Drug Induced Liver Injury with Use of Avacopan in ANCA Vasculitis – Results from Real-World Data
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic autoimmune vasculitis. Avacopan, a novel oral C5a receptor inhibitor, has emerged as an adjunct therapy…Abstract Number: 0720 • ACR Convergence 2025
Current State of Racial, Ethnic, Sex, and Geographical Diversity in ANCA-associated vasculitis and Giant Cell Arteritis Trials
Background/Purpose: Randomized controlled trials (RCTs) generate unbiased efficacy estimates and are required for regulatory approval. Understanding the degree to which they include racial, ethnic, sex,…Abstract Number: 1603 • ACR Convergence 2025
SGLT-2 Inhibitors are Associated with Lower Risk of End Stage Renal Disease (ESRD) and Lower Mortality in ANCA-associated Vasculitis With Kidney Involvement
Background/Purpose: ANCA-associated vasculitis encompasses three main conditions: Granulomatosis with Polyangiitis (GPA, previously called Wegener’s granulomatosis), Eosinophilic Granulomatosis with Polyangiitis (EGPA, previously called Churg-Strauss), and microscopic…Abstract Number: 2144 • ACR Convergence 2025
The Association Between Age at Diagnosis and Health-Related Quality of Life in ANCA-Associated Vasculitis
Background/Purpose: ANCA-associated vasculitis (AAV) is a chronic autoimmune condition that significantly impacts patients’ quality of life. It is unknown whether this impact varies based on…Abstract Number: 2520 • ACR Convergence 2025
Evolution in Risk Stratification for Renal Outcomes in ANCA-Associated Vasculitides Using Established Scores and Histopathological Criteria in a Large European Cohort
Background/Purpose: Glomerulonephritis is a common and threatening manifestation in ANCA-associated vasculitis (AAV). To assess the risk of end-stage kidney disease (ESKD), various scores have been…Abstract Number: 0725 • ACR Convergence 2025
Sinonasal Symptom Profiles Associated with Disease Activity in an International Cohort of Patients with ANCA-Associated Vasculitis
Background/Purpose: Sinus and nasal symptoms are common and associated with a higher risk of relapse in patients with ANCA-associated vasculitis (AAV). Previously, our group found…Abstract Number: 0721 • ACR Convergence 2025
Pulmonary Manifestations of Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Background/Purpose: There is limited knowledge of the epidemiology and complications of pulmonary manifestations in ANCA-associated vasculitis (AAV). This analysis focused describing the range of pulmonary…Abstract Number: 1604 • ACR Convergence 2025
Impact and risk factors of anti-rituximab antibodies in small-vessel vasculitis: a multicenter retrospective study
Background/Purpose: Small vessel vasculitis mainly includes ANCA-associated vasculitis (AAV) and cryoglobulinemic vasculitis (CV), leading to significant organ damage. Rituximab (RTX), an anti-CD20 monoclonal antibody, has…Abstract Number: 2452 • ACR Convergence 2025
Preliminary Safety, Efficacy, and Cellular Kinetics of CTA311, a CD19 Targeted Universal CAR-T Therapy, for Active Autoimmune Diseases
Background/Purpose: Systemic lupus erythematosus (SLE) and anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) are autoimmune conditions characterized by B cell activation, autoreactivity, and autoantibody production. CAR-T therapy…
- 1
- 2
- 3
- …
- 23
- Next Page »